Piton Therapeutics

Piton Therapeutics, Inc. is a biotechnology company based in Watertown, MA, founded in 2016. The company specializes in developing first-in-class small molecule therapeutics that target pathogenic pathways in the gut microbiome, focusing on chronic diseases with limited treatment options. Utilizing its proprietary Fathom Platform, Piton integrates AI and multiomics data analysis to decode microbiome signals, identify drug candidates, and validate them in-house.

Piton's pipeline includes orally dosed, gut-restricted small molecule drugs aimed at high-unmet-need indications such as Inflammatory Bowel Disease (IBD), Autism Spectrum Disorder (ASD), Parkinson’s Disease, and metabolic diseases like Type 2 Diabetes. The company is pioneering microbiome-focused precision medicines, with a strong emphasis on developing therapeutics that do not compromise systemic immunity. With a small team and a commitment to innovation, Piton is positioned as a leader in a new therapeutic category.